A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Conditions
Triple Negative Breast Cancer · Breast Cancer · Endometrial Cancer · Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Adenoid Cystic Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, United States
Contact: Study coordinator (Felipe Batalini, MD)Contact: Principal Investigator (Felipe Batalini, MD)UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States
Contact: Study coordinator (Ritesh Parajuli)Contact: Principal Investigator (Ritesh Parajuli)UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Contact: Study coordinator (Laura Huppert, MD)Contact: Principal Investigator (Laura Huppert, MD)UCLA David Geffen School of Medicine, Division of Hematology/Oncology, Santa Monica, California, United States
Contact: Study coordinator (Nicholas McAndrew, MD)Contact: Principal Investigator (Nicholas McAndrew, MD)Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Contact: Study coordinator (Pooja Advani, MD)Contact: Principal Investigator (Pooja Advani, MD)Florida Cancer Specialists, Sarasota, Florida, United States
Contact: Study coordinator (Judy Wang)Contact: Principal Investigator (Judy Wang)Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Hyo Han, MD)Contact: Principal Investigator (Hyo Han, MD)Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Contact: Study coordinator (Kevin Kalinsky, MD)Northwestern University, Chicago, Illinois, United States
Contact: Study coordinator (Patricia Robinson, MD)Contact: Principal Investigator (Patricia Robinson, MD)Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Contact: Study coordinator (Gerburg Wulf, MD)Contact: Principal Investigator (Gerburg Wulf, MD)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Antonio Giordano, MD, PhD)Henry Ford Health Hospital, Detroit, Michigan, United States
Contact: Study coordinator (Amy Weise, MD)Mayo Clinic - Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Roberto Leon-Ferre, MD)Contact: Principal Investigator (Roberto Leon-Ferre, MD)Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Contact: Study coordinator (Liawaty Ho, MD)Contact: Principal Investigator (Liawaty Ho, MD)New York University Langone Health, New York, New York, United States
Contact: Study coordinator (Nancy Chan, MD)ICHAN School of Medicine at Mount Sinai, New York, New York, United States
Contact: Study coordinator (Amy Tiersten)Contact: Principal Investigator (Amy Tiersten)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Nour Abuhadra, MD)Stephenson Cancer Center Oklahoma University Health, Oklahoma City, Oklahoma, United States
Contact: Study coordinator (Debra Richardson, MD)Contact: Principal Investigator (Debra Richardson, MD)Avera Cancer Institute, Sioux Falls, South Dakota, United States
Contact: Study coordinator (David C. Starks, MD)Contact: Principal Investigator (David C. Starks, MD)Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
Contact: Study coordinator (Erika P Hamilton, MD)Texas Oncology, P.A., Dallas, Texas, United States
Contact: Principal Investigator (Joyce O'Shaughnessy, MD)MD Anderson, Houston, Texas, United States
Contact: Study coordinator (Funda Meric-Bernstam)Contact: Principal Investigator (Funda Meric-Bernstam)Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact: Study coordinator (Kristen Kelley, MD)Contact: Principal Investigator (Kristen Kelley, MD)NEXT Oncology Virginia, Fairfax, Virginia, United States
Contact: Study coordinator (Alex Spira, MD, PhD)Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Jennifer Specht, MD)Summit Cancer Centers, Spokane, Washington, United States
Contact: Study coordinator (Arvind Chaudhry, MD, PhD)
Study leads
Robert Burger, MD
Study Director
Day One Biopharmaceuticals, Inc.